Article
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
HIV clinical trials - 1 Feb 2016
Calza Leonardo, Danese Ilaria, Magistrelli Eleonora, Colangeli Vincenzo, Manfredi Roberto, Bon Isabella, Re Maria Carla, Conti Matteo, Viale Pierluigi
Abstract excerpt
BACKGROUND: Nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapies may be useful in HIV-infected patients with resistance or intolerance to this class. METHODS: We performed an observational study of patients on suppressive antiretroviral therapy containing two NRTIs plus one ritonavir-boosted protease inhibitor who switched to a dual regimen containing raltegravir (400 mg twice daily)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.